---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021749"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:54:34.761791+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oragenics regains NYSE compliance, raises $16.5M, partners with Receptor.AI, advances Phase IIa trial

## Summary
- Regained NYSE American compliance on Oct 20, 2025, resolving equity deficiency and removing below-compliance indicator.
- Completed $16.5M gross capital raise via Series H Convertible Preferred Stock in July 2025; net proceeds ~$15.2M.
- Eliminated $3M note payable and restored stockholder equity above the $6M NYSE threshold.
- Formed strategic collaboration with Receptor.AI to use AI-driven discovery for pipeline beyond concussion.
- Anticipates Phase IIa trial initiation for ONP-002 in Q4 2025/Q1 2026 in Australia, with U.S. Phase IIb planning underway.

## SEC filing metadata
- accession: 0001493152-25-021749
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315225021749/0001493152-25-021749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315225021749/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021749
- JSON: https://secwatch.observer/filing/0001493152-25-021749.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021749.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.